Multisegment C-to-N Sequential Ser/Thr Ligation Using Mmoc-Protected N-Terminal Serine/Threonine Peptide Salicylaldehyde Esters.
Peptide chemists just got a new tool for assembling complex proteins. Tang and team rolled out a multisegment C-to-N sequential Ser/Thr ligation (STL) method using Mmoc-protected N-terminal serine and threonine peptide salicylaldehyde esters. Translation: building bigger, more intricate chains just got easier—and cleaner.
Org Lett
by Tang J, Shu Q, Wang J et al.
“Multisegment C-to-N Sequential Ser/Thr Ligation Using Mmoc-Protected N-Terminal Serine/Threonine Peptide Salicylaldehyde Esters. Tang J(1), Shu Q(1), Wang J(1), Li YM(1). Author information: (1)School of Food and Biological Engineering, Engineering Research Center of Bio-process, Ministry of Education, Key Laboratory of Animal Source of Anhui Province, Hefei University of Technology, Hefei 230009, China. Multisegment Ser/Thr ligation (STL) is an important technique for the chemical synthesis of proteins. The Fmoc group is currently widely used in multisegment STL to temporarily protect the reactive Ser or Thr residue at the N-terminus of the salicylaldehyde ester segment(s). However, the alkaline conditions required for Fmoc removal are incompatible with base-sensitive post-translational modifications and can readily induce aspartimide formation. Here, we report the Mmoc group-based multisegment STL. The Mmoc protection group can be rapidly removed under trifluoroacetic acid (TFA) and NH4I conditions, and this new strategy has been proven to efficiently synthesize proteins containing O-acetylation as well as Asp-Gly sequences.”
Here’s the headache this solves. Traditionally, the Fmoc group protects reactive serine or threonine on the N-terminus during STL. But Fmoc removal demands alkaline conditions. That’s a problem if your target protein has base-sensitive post-translational modifications (PTMs) or sequences prone to aspartimide formation. In other words, you risk wrecking the very protein you’re trying to make.
Key takeaway: The Mmoc protection group pops off under mild, acidic conditions using TFA and ammonium iodide. No harsh base. No side reactions trashing your modifications. This opens the door to efficient synthesis of proteins with tricky features like O-acetylation or Asp-Gly sequences—previously a nightmare with standard Fmoc protocols.
For researchers:
Faster, cleaner deprotection means less time troubleshooting and more time pushing experiments forward.
The method has already been validated for proteins with challenging PTMs—think modified peptides for advanced functional studies.
Could be a new go-to for labs aiming to push the boundaries of synthetic peptide research.
Anyone working on chemical protein synthesis, or just keeping up with new ligation strategies, should take a look at this method. For more on cutting-edge advances in peptide assembly and ligation techniques, check out our peptide research index.
Bottom line: More options and fewer obstacles for assembling the next generation of designer proteins.
Related Reading
The STRIDE Trial and Semaglutide: Implications for Clinical Vascular Practice.
News · J Med ChemStructure-Based Adaptation of a SARS-CoV-2 Neutralizing Peptide to New Virus Variants.
News · J Nucl MedCombining an α(v)β(6)-Targeted (177)Lu-Based Peptide Receptor Radionuclide Therapy with Olaparib to Boost Therapeutic Efficacy in Pancreatic Cancer.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.